Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422451 | 0.80 | CNR1 (0.38) | CNR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL126083 | 0.77 | MAPK1 (0.50) | ALDH1A1TSHRHPGDTP53KDM4E | |
| SCHEMBL749356 | 0.76 | CNR1 (0.42) | CNR1SMN1; SMN2HTTKDM4E | |
| SCHEMBL131452 | 0.76 | CA12 (0.41) | NPC1RAB9AALDH1A1ADORA3 | |
| SCHEMBL16277582 | 0.75 | P4HTM (0.45) | — | |
| SCHEMBL398283 | 0.74 | — | — | |
| SCHEMBL753368 | 0.72 | POLB (0.56) | CNR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL467358 | 0.72 | MLYCD (0.55) | SMN1; SMN2ALDH1A1HPGDALOX5MLYCD | |
| SCHEMBL1106971 | 0.71 | KDM4E (0.63) | GRM5NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL129083 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | claimed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | CHRM2 4124/4885GRM5 590/4885SIGMAR1 3548/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | CHRM2 4124/4885GRM5 590/4885SIGMAR1 3548/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | CHRM2 4124/4885GRM5 590/4885SIGMAR1 3548/4885 |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | CHRM2 4866/4885GRM5 3121/4885SIGMAR1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.